Bausch Health Companies Inc.
NYSE:BHCDrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $3.27B
- Beta
- 0.41
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$3.19
Volume 6.83M
Average 1.70M
BHC Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Bausch Health Companies Inc.NYSE: BHC
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow turns negative
Q2 FY2026 financing cash flow was -$49M, compared with $358M a year earlier. Trailing-twelve-month financing cash flow was -$1.1B. Over 3 fiscal years it compounded at +16.1% a year.
Context
- Financing cash flow amounted to 7.2% of revenue in FY2025, down 1.8 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near -$49M or moves back toward the trailing-twelve-month quarterly average of -$274.91M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (742M) USD
- Year-over-year change
- +14.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (742M) | +14.5% |
| FY2024 | 2024-12-31 | (868M) | -158.8% |
| FY2023 | 2023-12-31 | 1.48B | +411.2% |
| FY2022 | 2022-12-31 | (474M) | +68.7% |
| FY2021 | 2021-12-31 | (1.51B) | — |
Financing Cash Flow vs competitors
How BHC compares with its peers on the latest reported figures
- BHC's LTM Jun 2026 financing cash flow of $1.1B is the largest of the 11 companies compared; the peer median is $27.29M.
- Its year-over-year change of -1097.9% is the 10th highest of 11, against a peer median of -3.0%.
- Financing cash flow amounts to 10.1% of revenue for BHC, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.1B | -1097.9% | +16.1% | 10.1% | |
| LTM Jun 2026 | $659.43M | +231.0% | +66.5% | — | |
| LTM Jun 2026 | $578.8M | -6.1% | — | 14.0% | |
| LTM Mar 2026 | $322M | +95.2% | -37.6% | 8.7% | |
| LTM Mar 2026 | $275.7M | +74.2% | -13.9% | 49.3% | |
| LTM Jun 2026 | $227.55M | +0.1% | +21.1% | 16.8% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $215.86M | -407.9% | — | 9.2% |
| LTM Jun 2026 | $107.69M | -77.5% | +62.4% | 69.0% | |
| LTM Mar 2026 | $32.93M | -1330.4% | — | 5.5% | |
| LTM Mar 2026 | $21.65M | -107.9% | +24.7% | 2.3% | |
| LTM Jun 2025 | $11.22M | +9.2% | — | 1.9% | |
| Peer median (excluding BHC) | $27.29M | -3.0% | +22.9% | 9.2% | |
Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (937M) | (212M) | (611M) | (72M) | 120M |
| Depreciation & Amortization | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B |
| Deferred Income Tax | (225M) | (176M) | 51M | 66M | 80M |
| Stock-Based Compensation | 128M | 126M | 132M | 150M | 216M |
| Change in Working Capital | (128M) | (396M) | (582M) | 7M | (222.83M) |
| Accounts Receivables | (229M) | (57M) | (195M) | (216M) | (136.35M) |
| Inventory | (16M) | (198M) | (322M) | (267M) | (12.21M) |
| Accounts Payables | 121M | (75M) | 158M | 357M | (77.33M) |
| Other Working Capital | (4M) | (66M) | (223M) | 133M | 3.05M |
| Other Non-Cash Items | 1.04B | (1.46B) | 778M | 179M | (1.17M) |
| Operating Cash Flow | 1.43B | (728M) | 1.03B | 1.6B | 1.4B |
| Capital Expenditures | (283M) | (268M) | (272M) | (337M) | (397M) |
| Acquisitions (Net) | 0 | (45M) | (1.89B) | 0 | 0 |
| Purchases of Investments | (19M) | (17M) | (27M) | (12M) | (11M) |
| Sales of Investments | 15M | 22M | 26M | 14M | 8M |
| Other Investing Activities | 682M | (45M) | (39M) | (119M) | (195M) |
| Investing Cash Flow | 409M | (303M) | (2.15B) | (454M) | (595M) |
| Debt Repayment | (1.34B) | (1.01B) | 1.58B | (799M) | (648.15M) |
| Common Stock Issued | 0 | 675M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | (26M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (173M) | (139M) | (106M) | (43M) | (93.85M) |
| Financing Cash Flow | (1.51B) | (474M) | 1.48B | (868M) | (742M) |
| Effect of Forex Changes | (19M) | (23M) | 9M | (36M) | 61M |
| Net Change in Cash | 303M | (1.53B) | 371M | 239M | 124M |
| Free Cash Flow | 1.14B | (996M) | 760M | 1.26B | 1B |
Bausch Health Companies Inc.
NYSE:BHC
Intrinsic Alpha fair value
Locked
Current Price
$8.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.